Loading...
| A00338 | Pages: 187 | Sep 2021 | 11157 Views | | |
| Author(s) : Apoorva Srivastava , Onkar Sumant | Tables: 90 | Charts: 45 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Antipsychotic Drugs Market
Request Now !The global antipsychotic drugs market size was valued at $12,417.60 million in 2020, and is estimated to reach $26,041.00 million by 2030, growing at a CAGR of 8.0% from 2021 to 2030. Antipsychotic drugs are medications used in treatment of psychosis including schizophrenia and bipolar disorder. Psychosis is a critical symptom that occurs due to mental illness, including loss with reality affecting how one processes information.
COVID-19 have had a huge impact on the antipsychotic drugs market and caused disruption to care and treatment. Some specialized mental health provision has been cut to increase capacity to treat physical impact of COVID-19. A number of general hospital psychiatric wards have been converted into COVID-19 wards, meaning large number of severally ill people are moved out.
Get more information on this report : Request Sample Pages
In Buenos Aires, Argentina, a neurological institute reported over 99% reduction in patient encounters since COVID-19. Community-based psychosocial support activities have also been severely impacted with many countries seeing groups, associations, and community-based initiatives that brought people together regularly before the pandemic unable to meet for months. Demand for face-to-face mental health services has reportedly decreased due to fear of infection, especially among older people. In addition, many services have had to switch to remote healthcare, providing consultations through digital platforms or by phone, to varying degrees of success. Moreover, many patients have been nervous about going to the pharmacy to pick up prescriptions, and physicians can recommend useful over-the-counter medicines and provide instructions on how to administer prescription and non-prescription medicines all through telemedicine. This is anticipated to increase the market growth in the future.
Increase in prevalence of mental disorders, rise in geriatric population, and growth in awareness program regarding mental health drive the market growth. Moreover, growing awareness about mental disorders through education and advocacy for more respect of human rights and less stigma drive growth of the global antipsychotic drugs market. However, rise in cost of mental health programs and substance abuse is expected to hamper the market growth.
The global market for antipsychotic drugs is anticipated to witness positive growth trends, owing to strong increase in prevalence of psychotic disorders. This increase in number of patient pools across the globe is anticipated to drive growth of the market. For instance, according to the Global Burden of Disease Study, there is an increase in disease burden due to schizophrenia globally, especially in middle-income countries and low-income countries.
According to the data published by Medscape in 2019, lifelong prevalence rate of bipolar disorder was estimated to be 0.3–1.5%. However, in recent years, the prevalence of the bipolar disorder has increased substantially. This has led several pharmaceutical companies to engage in R&D of antipsychotic medications, leading to new product launches. Such factors are expected to drive growth of the global antipsychotic drugs market during the forecast period.
Get more information on this report : Request Sample Pages
The global antipsychotic drugs market is segmented into therapeutic class, application, distribution channel, and region. By therapeutic class, the market is categorized into first-generation and second-generation. By application, it is categorized into schizophrenia, dementia, bipolar disorder, depression and others. By distribution channel, it is divided into a hospital pharmacies, retail pharmacies, and online pharmacies.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Get more information on this report : Request Sample Pages
Depending on therapeutic class, the second-generation segment was the major revenue contributor in 2020, and is anticipated to remain dominant during the forecast period. Long-acting injectable antipsychotic drugs have the efficacy of daily pills and eliminate the need to monitor drug intake of patients. Hence, the number of benefits attributed to this form of antipsychotic has led to a greater degree of product adoption.
On the basis of application, the schizophrenia segment dominated the market in 2020, and is anticipated to continue this trend during the forecast period. This is attributed to rapidly increase in incidences of schizophrenic disorders, owing to change in lifestyle.
Get more information on this report : Request Sample Pages
North America was the largest shareholder in the global antipsychotic drugs market in 2020, owing to its well-established healthcare infrastructure, surge in adoption of mental healthcare services, increase in geriatric population, and rise in prevalence of mental diseases. However, Asia-Pacific is anticipated to register the highest CAGR during the forecast period, owing to increase in health awareness, development in healthcare infrastructure, and rise in number of hospitals equipped with advanced medical facilities.
The key players operating in the global market include Eli Lily and Company, AstraZeneca plc, GlaxoSmithKline plc, Johnson & Johnson, Otsuka Pharmaceutical Co, Ltd., Pfizer Inc., AbbVie Inc., Bristol-Myers Squibb, Teva Pharmaceuticals, and Dr. Reddy's Laboratories.
Get more information on this report : Request Sample Pages
Key Benefits For Stakeholders
Key Market Segments
By Therapeutic Class
By Application
By Distribution Channel
By Region
Key Market Players
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five forces analysis
3.3.1.Top player positioning
3.4.Market dynamics
3.4.1.Drivers, restraints, and opportunities
3.4.2.Drivers
3.4.2.1.Rise in prevalence of mental health disorders
3.4.2.2.Increase in awareness of psychological disorders
3.4.3.Restraint
3.4.3.1.Side-effects of antipsychotic therapeutics
3.4.4.Opportunity
3.4.4.1.High growth potential in developing economies
3.5.Impact of COVID-19 on the antipsychotic drugs market
3.5.1.Overview
3.5.2.Impact analysis
CHAPTER 4:ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS
4.1.Overview
4.1.1.Market size and forecast
4.2.First-generation
4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Second-generation
4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
CHAPTER 5:ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION
5.1.Overview
5.1.1.Market size and forecast
5.2.Schizophrenia
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Dementia
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Bipolar disorder
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Depression
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Others
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
CHAPTER 6:ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1.Overview
6.1.1.Market size and forecast
6.2.Hospital Pharmacies
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.2.2.1.Market size and forecast, by application
6.3.Retail Pharmacies
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.3.2.1.Market size and forecast, by application
6.4.Online Pharmacies
6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country
6.4.2.1.Market size and forecast, by application
CHAPTER 7:ANTIPSYCHOTIC DRUGS MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key opportunities and forecast
7.2.2.Market size and forecast, by country
7.2.3.Market size and forecast, by therapeutic class
7.2.4.Market size and forecast, by application
7.2.5.Market size and forecast, by distribution channel
7.2.5.1.U.S.
7.2.5.1.1.U.S. market size and forecast, by therapeutic class
7.2.5.1.2.U.S. market size and forecast, by application
7.2.5.1.3.U.S. market size and forecast, by distribution channel
7.2.5.2.Canada
7.2.5.2.1.Canada market size and forecast, by therapeutic class
7.2.5.2.2.Canada market size and forecast, by application
7.2.5.2.3.Canada market size and forecast, by distribution channel
7.2.5.3.Mexico
7.2.5.3.1.Mexico market size and forecast, by therapeutic class
7.2.5.3.2.Mexico market size and forecast, by application
7.2.5.3.3.Mexico market size and forecast, by distribution channel
7.3.Europe
7.3.1.Key opportunities and forecast
7.3.2.Market size and forecast, by country
7.3.3.Market size and forecast, by therapeutic class
7.3.4.Market size and forecast, by application
7.3.5.Market size and forecast, by distribution channel
7.3.5.1.Germany
7.3.5.1.1.Germany market size and forecast, by therapeutic class
7.3.5.1.2.Germany market size and forecast, by application
7.3.5.1.3.Germany market size and forecast, by distribution channel
7.3.5.2.France
7.3.5.2.1.France market size and forecast, by therapeutic class
7.3.5.2.2.France market size and forecast, by application
7.3.5.2.3.France market size and forecast, by distribution channel
7.3.5.3.UK
7.3.5.3.1.UK market size and forecast, by therapeutic class
7.3.5.3.2.UK market size and forecast, by application
7.3.5.3.3.UK market size and forecast, by distribution channel
7.3.5.4.Italy
7.3.5.4.1.Italy market size and forecast, by therapeutic class
7.3.5.4.2.Italy market size and forecast, by application
7.3.5.4.3.Italy market size and forecast, by distribution channel
7.3.5.5.Spain
7.3.5.5.1.Spain market size and forecast, by therapeutic class
7.3.5.5.2.Spain market size and forecast, by application
7.3.5.5.3.Spain market size and forecast, by distribution channel
7.3.5.6.Rest of Europe
7.3.5.6.1.Rest of Europe market size and forecast, by therapeutic class
7.3.5.6.2.Rest of Europe market size and forecast, by application
7.3.5.6.3.Rest of Europe market size and forecast, by distribution channel
7.4.Asia-Pacific
7.4.1.Key opportunities and forecast
7.4.2.Market size and forecast, by country
7.4.3.Market size and forecast, by therapeutic class
7.4.4.Market size and forecast, by application
7.4.5.Market size and forecast, by distribution channel
7.4.5.1.Japan
7.4.5.1.1.Japan market size and forecast, by therapeutic class
7.4.5.1.2.Japan market size and forecast, by distribution channel
7.4.5.1.3.Japan market size and forecast, by distribution channel
7.4.5.2.China
7.4.5.2.1.China market size and forecast, by therapeutic class
7.4.5.2.2.China market size and forecast, by application
7.4.5.2.3.China market size and forecast, by distribution channel
7.4.5.3.Australia
7.4.5.3.1.Australia market size and forecast, by therapeutic class
7.4.5.3.2.Australia market size and forecast, by application
7.4.5.3.3.Australia market size and forecast, by distribution channel
7.4.5.4.India
7.4.5.4.1.India market size and forecast, by therapeutic class
7.4.5.4.2.India market size and forecast, by application
7.4.5.4.3.India market size and forecast, by distribution channel
7.4.5.5.South Korea
7.4.5.5.1.South Korea market size and forecast, by therapeutic class
7.4.5.5.2.South Korea market size and forecast, by application
7.4.5.5.3.South Korea market size and forecast, by distribution channel
7.4.5.6.Rest of Asia-Pacific
7.4.5.6.1.Rest of Asia-Pacific market size and forecast, by therapeutic class
7.4.5.6.2.Rest of Asia-Pacific market size and forecast, by application
7.4.5.6.3.Rest of Asia-Pacific market size and forecast, by distribution channel
7.5.LAMEA
7.5.1.Key opportunities and forecast
7.5.2.Market size and forecast, by country
7.5.3.Market size and forecast, by therapeutic class
7.5.4.Market size and forecast, by distribution channel
7.5.5.Market size and forecast, by distribution channel
7.5.5.1.Brazil
7.5.5.1.1.Brazil market size and forecast, by therapeutic class
7.5.5.1.2.Brazil market size and forecast, by application
7.5.5.1.3.Brazil market size and forecast, by distribution channel
7.5.5.2.Saudi Arabia
7.5.5.2.1.Saudi Arabia market size and forecast, by therapeutic class
7.5.5.2.2.Saudi Arabia market size and forecast, by application
7.5.5.2.3.Saudi Arabia market size and forecast, by distribution channel
7.5.5.3.South Africa
7.5.5.3.1.South Africa market size and forecast, by therapeutic class
7.5.5.3.2.South Africa market size and forecast, by application
7.5.5.3.3.South Africa market size and forecast, by distribution channel
7.5.5.4.Rest of LAMEA
7.5.5.4.1.Rest of LAMEA market size and forecast, by therapeutic class
7.5.5.4.2.Rest of LAMEA market size and forecast, by application
7.5.5.4.3.Rest of LAMEA market size and forecast, by distribution channel
CHAPTER 8:COMPANY PROFILES
8.1.ABBVIE INC. (ALLERGAN INC.)
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments
8.2.ALKERMES PLC.
8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments
8.3.ASTRAZENECA PLC.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Business performance
8.4.BRISTOL-MYERS SQUIBB
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.5.DR. REDDY’S LABORATORIES LIMITED
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.ELI LILLY AND COMPANY
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.7.JOHNSON & JOHNSON (JANSSEN PHARMACEUTICALS)
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments
8.8.OTSUKA HOLDINGS CO., LTD. (OTSUKA PHARMACEUTICAL CO., LTD.)
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments
8.9.PFIZER INC.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.10.TEVA PHARMACEUTICAL INDUSTRIES LTD.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
LIST OF TABLES
TABLE 01.ANTIPSYCHOTIC DRUGS MARKET REVENUE, BY THERAPEUTIC CLASS, 2020–2030 ($MILLION)
TABLE 02.ANTIPSYCHOTIC DRUGS MARKET REVENUE FOR FIRST-GENERATION, BY REGION, 2020–2030($MILLION)
TABLE 03.ANTIPSYCHOTIC DRUGS MARKET REVENUE FOR SECOND-GENERATIONS, BY REGION, 2020–2028($MILLION)
TABLE 04.ANTIPSYCHOTIC DRUGS MARKET REVENUE, BY APPLICATION, 2020–2030 ($MILLION)
TABLE 05.ANTIPSYCHOTIC DRUGS MARKET REVENUE FOR SCHIZOPHRENIA, BY REGION, 2020–2030($MILLION)
TABLE 06.ANTIPSYCHOTIC DRUGS MARKET REVENUE FOR DEMENTIA, BY REGION, 2020–2028($MILLION)
TABLE 07.ANTIPSYCHOTIC DRUGS MARKET REVENUE FOR BIPOLAR DISORDER, BY REGION, 2020–2030($MILLION)
TABLE 08.ANTIPSYCHOTIC DRUGS MARKET REVENUE FOR DEPRESSION, BY REGION, 2020–2030 ($MILLION)
TABLE 09.ANTIPSYCHOTIC DRUGS MARKET REVENUE FOR OTHERS, BY REGION, 2020–2030 ($MILLION)
TABLE 10.ANTIPSYCHOTIC DRUGS MARKET REVENUE, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 11.HOSPITAL PHARMACIES FOR ANTIPSYCHOTIC DRUGS MARKET REVENUE, BY REGION, 2020–2030($MILLION)
TABLE 12.HOSPITAL PHARMACIES FOR ANTIPSYCHOTIC DRUGS MARKET REVENUE, BY APPLICATION, 2020–2030($MILLION)
TABLE 13.RETAIL PHARMACIES FOR ANTIPSYCHOTIC DRUGS MARKET REVENUE, BY REGION, 2020–2030 ($MILLION)
TABLE 14.RETAIL PHARMACIES FOR ANTIPSYCHOTIC DRUGS MARKET REVENUE, BY APPLICATION, 2020–2030($MILLION)
TABLE 15.ONLINE PHARMACIES FOR ANTIPSYCHOTIC DRUGS MARKET REVENUE, BY REGION, 2020–2030 ($MILLION)
TABLE 16.ONLINE PHARMACIES FOR ANTIPSYCHOTIC DRUGS MARKET REVENUE, BY APPLICATION, 2020–2030($MILLION)
TABLE 17.ANTIPSYCHOTIC DRUGS MARKET, BY REGION, 2020–2030($MILLION)
TABLE 18.NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 19.NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 20.NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION CHANNEL, 2020–2030($MILLION)
TABLE 21.NORTH AMERICA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 22.U.S. ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 23.U.S. ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 24.U.S. ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 25.CANADA ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 26.CANADA ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 27.CANADA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 28.MEXICO ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 29.MEXICO ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 30.MEXICO ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 31.EUROPE ANTIPSYCHOTIC DRUGS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 32.EUROPE ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 33.EUROPE ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 34.EUROPE ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 35.GERMANY ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 36.GERMANY ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 37.GERMANY ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 38.FRANCE ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 39.FRANCE ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 40.FRANCE ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 41.UK ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 42.UK ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 43.UK ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 44.ITALY ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 45.ITALY ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 46.ITALY ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 47.SPAIN ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 48.SPAIN ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 49.SPAIN ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 50.REST OF EUROPE ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 51.REST OF EUROPE ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 52.REST OF EUROPE ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 53.ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 54.ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 55.ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 56.ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 57.JAPAN ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 58.JAPAN ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 59.JAPAN ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 60.CHINA ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 61.CHINA ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 62.CHINA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 63.AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 64.AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 65.AUSTRALIA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 66.INDIA ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 67.INDIA ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 68.INDIA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 69.SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 70.SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 71.SOUTH KOREA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 72.REST OF ASIA-PACIFIC ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 73.REST OF ASIA-PACIFC ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 74.REST OF ASIA-PACIFC ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 75.LAMEA ANTIPSYCHOTIC DRUGS MARKET, BY COUNTRY, 2020–2030($MILLION)
TABLE 76.LAMEA ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 77.LAMEA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 78.LAMEA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 79.BRAZIL ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 80.BRAZIL ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 81.BRAZIL ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 82.SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 83.SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 84.SAUDI ARABIA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 85.SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 86.SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 87.SOUTH AFRICA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 88.REST OF LAMEA ANTIPSYCHOTIC DRUGS MARKET, BY THERAPEUTIC CLASS, 2020–2030($MILLION)
TABLE 89.REST OF LAMEA ANTIPSYCHOTIC DRUGS MARKET, BY APPLICATION, 2020–2030($MILLION)
TABLE 90.REST OF LAMEA ANTIPSYCHOTIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030($MILLION)
TABLE 91.ABBVIE: COMPANY SNAPSHOT
TABLE 92.ABBVIE: PRODUCT SEGMENTS
TABLE 93.ABBVIE: PRODUCT PORTFOLIO
TABLE 94.ABBVIE: KEY DEVELOPMENTS
TABLE 95.ALKERMES: COMPANY SNAPSHOT
TABLE 96.ALKERMES: PRODUCT SEGMENTS
TABLE 97.ALKERMES: PRODUCT PORTFOLIO
TABLE 98.ALKERMES: KEY DEVELOPMENTS
TABLE 99.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 100.ASTRAZENECA: OPERATING SEGMENTS
TABLE 101.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 102.BRISTOL: COMPANY SNAPSHOT
TABLE 103.BRISTOL: PRODUCT SEGMENTS
TABLE 104.BRISTOL: PRODUCT PORTFOLIO
TABLE 105.REDDY: COMPANY SNAPSHOT
TABLE 106.REDDY: OPERATING BUSINESS SEGMENTS
TABLE 107.REDDY: PRODUCT PORTFOLIO
TABLE 108.REDDY: KEY DEVELOPMENTS
TABLE 109.LILLY: COMPANY SNAPSHOT
TABLE 110.LILLY: OPERATING SEGMENTS
TABLE 111.LILLY: PRODUCT PORTFOLIO
TABLE 112.JOHNSON: COMPANY SNAPSHOT
TABLE 113.JOHNSON: PRODUCT SEGMENTS
TABLE 114.JOHNSON: PRODUCT PORTFOLIO
TABLE 115.JOHNSON: KEY DEVELOPMENTS
TABLE 116.OTSUKA: COMPANY SNAPSHOT
TABLE 117.OTSUKA: OPERATING SEGMENTS
TABLE 118.OTSUKA: PRODUCT PORTFOLIO
TABLE 119.OTSUKA: KEY DEVELOPMENTS
TABLE 120.PFIZER: COMPANY SNAPSHOT
TABLE 121.PFIZER: OPERATING BUSINESS SEGMENTS
TABLE 122.PFIZER: PRODUCT PORTFOLIO
TABLE 123.TEVA: COMPANY SNAPSHOT
TABLE 124.TEVA: OPERATING SEGMENTS
TABLE 125.TEVA: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.ANTIPSYCHOTIC DRUGS MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
FIGURE 06.MODERATE BARGAINING POWER OF BUYERS
FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08.MODERATE THREAT OF NEW ENTRANTS
FIGURE 09.MODERATE THREAT OF SUBSTITUTION
FIGURE 10.MODERATE COMPETITIVE RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.DRIVERS, RESTRAINTS, AND OPPORTUNITIES
FIGURE 13.ANTIPSYCHOTIC DRUGS MARKET REVENUE FOR FIRST-GENERATION, BY COUNTRY, 2020–2030(%)
FIGURE 14.ANTIPSYCHOTIC DRUGS MARKET REVENUE FOR SECOND-GENERATIONS, BY COUNTRY, 2020–2030(%)
FIGURE 15.ANTIPSYCHOTIC DRUGS MARKET REVENUE FOR SCHIZOPHRENIA, BY COUNTRY, 2020–2030(%)
FIGURE 16.ANTIPSYCHOTIC DRUGS MARKET REVENUE FOR DEMENTIA, BY COUNTRY, 2020–2030(%)
FIGURE 17.ANTIPSYCHOTIC DRUGS MARKET REVENUE FOR BIPOLAR DISORDER, BY COUNTRY, 2020–2030(%)
FIGURE 18.ANTIPSYCHOTIC DRUGS MARKET REVENUE FOR DEPRESSION, BY COUNTRY, 2020–2030(%)
FIGURE 19.ANTIPSYCHOTIC DRUGS MARKET REVENUE FOR OTHERS, BY COUNTRY, 2020–2030 (%)
FIGURE 20.HOSPITAL PHARMACIES FOR ANTIPSYCHOTIC DRUGS MARKET REVENUE, BY COUNTRY, 2020–2030(%)
FIGURE 21.RETAIL PHARMACIES FOR ANTIPSYCHOTIC DRUGS MARKET REVENUE, BY COUNTRY, 2020–2030(%)
FIGURE 22.ONLINE PHARMACIES FOR ANTIPSYCHOTIC DRUGS MARKET REVENUE, BY COUNTRY, 2020–2030(%)
FIGURE 23.ABBVIE: NET SALES, 2018–2020 ($MILLION)
FIGURE 24.ABBVIE: REVENUE SHARE BY REGION, 2020(%)
FIGURE 25.ALKERMES: NET SALES, 2018–2020 ($MILLION)
FIGURE 26.ALKERMES: REVENUE SHARE BY REGION, 2020(%)
FIGURE 27.ASTRAZENECA: NET SALES, 2018–2020 ($MILLION)
FIGURE 28.ASTRAZENECA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 39.ASTRAZENECA: REVENUE SHARE BY REGION, 2020(%)
FIGURE 30.BRISTOL: NET SALES, 2018–2020 ($MILLION)
FIGURE 31.BRISTOL: REVENUE SHARE BY REGION, 2020(%)
FIGURE 32.REDDY: NET SALES, 2019–2021 ($MILLION)
FIGURE 33.REDDY: REVENUE SHARE BY SEGMENT, 2021 (%)
FIGURE 34.REDDY: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 35.LILLY: NET SALES, 2018–2020 ($MILLION)
FIGURE 36.LILLY: REVENUE SHARE BY REGION, 2020(%)
FIGURE 37.JOHNSON: NET SALES, 2018–2020 ($MILLION)
FIGURE 38JOHNSON: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 39.JOHNSON: REVENUE SHARE BY REGION, 2020(%)
FIGURE 40.OTSUKA: NET SALES, 2018–2020 ($MILLION)
FIGURE 41.PFIZER: NET SALES, 2018–2020 ($MILLION)
FIGURE 42.PFIZER: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 43.TEVA: NET SALES, 2018–2020 ($MILLION)
FIGURE 44.TEVA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 45.TEVA: REVENUE SHARE BY REGION, 2020(%)
The antipsychotic drugs market gained prominence in 2020, and is expected to witness a significant rise in the near future. This is attributed to rise in incidence of mental disorders, increase in work pressure in offices due to COVID-19, and surge in awareness toward benefits of mental health services. However, side effects such as weight gain, increase in cholesterol levels and risk of diabetes caused due to antipsychotic drugs hamper the market growth.
In recent years, there have been significant changes in R&D of antipsychotic medications. This is attributes to increase in awareness among individuals regarding economic burden that mental disorders exert upon the healthcare system. This has led more and more individuals to demand more effective treatment for psychiatric illnesses. However, one of the most critical factors that resulted in high unmet patient needs and a significant lack of adoption of antipsychotic medications is non-adherence toward medications. Furthermore, several patients who are prescribed antipsychotics often do not follow prescription guidelines and often suffer from relapses of psychotic episodes due to this non-adherence.
Hence, many biopharmaceutical companies have undertaken R&D and launches of long-acting injectable versions of antipsychotics. These long-acting injectable antipsychotic drugs have efficacy of daily pills and eliminate the need to monitor drug intake in patients. Hence, number of benefits attributed to this form of antipsychotic has led to a greater degree of product adoption.
Another key factors expected to drive demand for antipsychotic drugs is rise in mental health issues, owing to stress, peer pressure, and social & economic hardships. Moreover, a negative work environment can lead to mental health problems, which propels the market growth.
A. The total market value of antipsychotic drugs market is $12,417.60 million in 2020.
A. The forcast period for antipsychotic drugs market is 2021 to 2030
A. The market value of antipsychotic drugs market in 2030 is $26,041.00 million.
A. The base year is 2020 in antipsychotic drugs market
A. Top companies such as Abbvie inc., Johnson & Johnson, Dr. Reddy’s laboratories limited, Bristol-Myers Squibb, and Astrazeneca Plc held a high market position in 2020. These key players held a high market postion owing to the strong geographical foothold in different regions.
A. In therapeutic class second-generation segment was the major revenue contributor in 2020, and is anticipated to remain dominant during the forecast period. Long-acting injectable antipsychotic drugs have the efficacy of daily pills and eliminate the need to monitor drug intake of patients. Hence, the number of benefits attributed to this form of antipsychotic has led to a greater degree of product adoption.
A. Rise in prevalence of mental health disorders, increase in awareness of psychological disorders, and high growth potential in developing economies drive growth of the global antipsychotic drugs market. However, side effects attributed to antipsychotic therapeutics are expected to hinder market growth.
A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the emerging countries and increase in health awareness, development in healthcare infrastructure, and rise in number of hospitals equipped with advanced medical facilities
A. Antipsychotic is a class of medication used to treat psychosis, including hallucinations, delusions, paranoia, or disordered thought, schizophrenia, and bipolar disorder. It is also used to treat Alzheimer's and other memory-related diseases. Antipsychotic drugs act by controlling production of dopamine in the brain.
A. schizophrenia, dementia, bipolar disorder, depression, and others
Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
